CO
COH.AU Cochlear Ltd
- Market cap
- AUD 9.39B
- P/E
- 63.8x
- P/B
- 5.40x
- ROE
- 8.5%
- Dividend yield
- 2.99%
- Fundamental score
- 2.5/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is COH.AU undervalued?
Graham numberThe Graham number of Cochlear Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cochlear Ltd fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (8.5%), below 10%.
ROA 1/1
Return on assets (5.7%) is above the industry median (-35.3%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-62.2%) is not above the 5-year average (-14.7% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-62.2%) is below the industry median (24.9%).
Revenue Growth 1/2
Revenue grew 6.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (12.2%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 22.8x against interest expense, well covered.
PE vs Market 0/1
PE (63.8x) is above the market median (15.0x).
PE vs Industry 0/1
PE (63.8x) is above the industry median (36.4x).
PBV 0/1
Price to book (5.4x) is above the industry median (4.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 344.6, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (3.0%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 6 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 0/1
Payout ratio is 190.9%, above 90% of earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cochlear Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cochlear Ltd
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist…
Full company profileCochlear Ltd financial statements
Cochlear Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.25B | 1.36B | 1.43B | 1.35B | 1.49B | 1.64B | 1.94B | 2.24B | 2.34B | 2.33B |
| Gross Profit | 895M | 1.00B | 1.08B | 1.01B | 1.08B | 1.23B | 1.47B | 1.67B | 1.73B | 1.65B |
| Operating Income | 315M | 345M | 353M | 259M | 328M | 362M | 390M | 522M | 406M | 301M |
| EBITDA | 348M | 383M | 409M | -183M | 452M | 475M | 487M | 580M | 620M | 407M |
| Net Income | 224M | 246M | 277M | -238M | 327M | 289M | 301M | 357M | 389M | 147M |
| EPS | 3.89 | 4.27 | 4.79 | -4.00 | 4.97 | 4.40 | 4.56 | 5.43 | 5.94 | 2.25 |
| Balance Sheet | ||||||||||
| Total Assets | 1.14B | 1.16B | 1.38B | 2.58B | 2.43B | 2.47B | 2.57B | 2.75B | 2.83B | 2.60B |
| Total Liabilities | 593M | 546M | 653M | 1.18B | 737M | 779M | 820M | 905M | 875M | 862M |
| Shareholders' Equity | 544M | 611M | 726M | 1.40B | 1.69B | 1.69B | 1.75B | 1.84B | 1.95B | 1.74B |
| Cash & Short-term Investments | 89.5M | 61.5M | 78.6M | 930M | 610M | 629M | 556M | 514M | 276M | 188M |
| Total Debt | 219M | 148M | 182M | 705M | 264M | 254M | 202M | 244M | 236M | 213M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 260M | 258M | 296M | -158M | 265M | 377M | 362M | 389M | 238M | 368M |
| Capital Expenditure | 53.5M | 28.4M | 59.9M | 131M | 66.7M | 77.2M | 95.9M | 62.4M | 62.4M | 61.1M |
| Free Cash Flow | 206M | 230M | 236M | -288M | 199M | 299M | 267M | 326M | 175M | 307M |
| Ratios | ||||||||||
| ROE | 41.1% | 40.2% | 38.1% | -17.0% | 19.3% | 17.2% | 17.2% | 19.4% | 19.9% | 8.5% |
| ROA | 19.7% | 21.2% | 20.1% | -9.2% | 13.5% | 11.7% | 11.7% | 13.0% | 13.8% | 5.7% |
| Net Profit Margin | 17.8% | 18.0% | 19.4% | -17.6% | 21.9% | 17.6% | 15.5% | 16.0% | 16.6% | 6.3% |
| Debt to Equity | 0.40x | 0.24x | 0.25x | 0.50x | 0.16x | 0.15x | 0.12x | 0.13x | 0.12x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cochlear Ltd dividends
- Dividend yield
- 2.99%
- Forward dividend
- 2.60 AUD
- Payout ratio
- 190.9%
- Ex-dividend date
- Sep 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | AUD 281M | 4.29 | 190.9% |
| 2025 | AUD 278M | 4.25 | 71.5% |
| 2024 | AUD 246M | 3.74 | 68.9% |
| 2023 | AUD 197M | 3.00 | 65.7% |
| 2022 | AUD 194M | 2.95 | 67.1% |
| 2021 | AUD 75.6M | 1.15 | 23.2% |
| 2020 | AUD 194M | 3.25 | - |
| 2019 | AUD 182M | 3.15 | 65.7% |
| 2018 | AUD 161M | 2.80 | 65.5% |
| 2017 | AUD 144M | 2.50 | 64.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cochlear Ltd
- Insiders 0.58%
- Institutions 60.74%
- Public & others 38.68%
- Shares outstanding 65.4M
- Free float 65.1M
Top funds holding COH.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 969K | 1.47% | - | Oct 2020 |
| Invesco Oppenheimer International Small-Mid Company Fund | 668K | 1.02% | - | Jan 2021 |
| Franklin Global Tr-Franklin International Growth Fund | 540K | 0.82% | - | Jan 2021 |
| BNY Mellon International Stock Fd | 431K | 0.66% | - | Nov 2020 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 409K | 0.62% | - | Dec 2020 |
| Aberdeen Standard SICAV I-Asia Equity Fund | 377K | 0.57% | - | Feb 2021 |
| Bridge Builder Tr-Bridge Builder International Equity Fd | 314K | 0.48% | - | Dec 2020 |
| Price (T.Rowe) International Discovery Fund | 309K | 0.47% | - | Jan 2021 |
| iShares Core MSCI EAFE ETF | 294K | 0.45% | - | Feb 2021 |
| Baillie Gifford International Alpha Fund | 221K | 0.34% | - | Dec 2020 |
Cochlear Ltd company profile
- Company name
- Cochlear Ltd
- Ticker
- COH.AU
- ISIN
- AU000000COH5
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,400
- Fiscal year end
- June
- Address
- 1 University Avenue, Sydney, NSW, Australia, 2109
- Phone
- 61 2 9428 6555
- Website
- cochlear.com
About Cochlear Ltd
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and services under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Ltd management
10- Mr. Diggory William Howitt BE (Hons), MBACEO, MD, President & Executive Director · born 1967
- Dr. Sarah ThomChief Financial Officer
- Mr. Jan Janssen MSc Elec EngChief Technology Officer · born 1965
- Ms. Karen O'DriscollChief Information Officer
- Ms. Kristina DevonVP of Corporate Strategy & Investor Relations
- Mr. Rob McGroryGroup General Counsel & Company Secretary
- Ms. Jennifer StewartVice President of Communications, Brand & Digital Marketing
- Mr. Dean PhizackleaSenior Vice President of Global Strategic Marketing
- Ms. Sabina SopovChief People Officer, Global People & Culture
- Mr. Greg Bodkin BE (Hons), MComm (UNSW)Senior Vice President of Global Supply Chain